Cargando…

Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensin-converting enzyme 2 (ACE2) expressed on the cell surface, which is then processed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung-Hee, Kim, Jiseon, Jang, Ji Yun, Noh, Hyuna, Park, Jisun, Jeong, Haengdueng, Jeon, Donghun, Uhm, Chanyang, Oh, Heeju, Cho, Kyungrae, Jeon, Yoon, On, Dain, Yoon, Suhyeon, Lim, Soo-Yeon, Kim, Sol Pin, Lee, Youn Woo, Jang, Hui Jeong, Park, In Ho, Oh, Jooyeon, Seo, Jung Seon, Kim, Jeong Jin, Seok, Sang-Hyuk, Lee, Yu Jin, Hong, Seung-Min, An, Se-Hee, Kim, Seo Yeon, Kim, Young Been, Hwang, Ji-Yeon, Lee, Hyo-Jung, Kim, Hong Bin, Choi, Kang-Seuk, Park, Jun Won, Seo, Jun-Young, Yun, Jun-Won, Shin, Jeon-Soo, Lee, Ho-Young, Kim, Kyoungmi, Lee, Daekee, Lee, Ho, Nam, Ki Taek, Seong, Je Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706212/
https://www.ncbi.nlm.nih.gov/pubmed/36457995
http://dx.doi.org/10.3389/fimmu.2022.1055811
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensin-converting enzyme 2 (ACE2) expressed on the cell surface, which is then processed by type II transmembrane serine protease. However, ACE2 does not react to SARS-CoV-2 in inbred wild-type mice, which poses a challenge for preclinical research with animal models, necessitating a human ACE2 (hACE2)-expressing transgenic mouse model. Cytokeratin 18 (K18) promoter-derived hACE2 transgenic mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J] are widely used for research on SARS-CoV-1, MERS-CoV, and SARS-CoV-2. However, SARS-CoV-2 infection is lethal at ≥10(5) PFU and SARS-CoV-2 target cells are limited to type-1 alveolar pneumocytes in K18-hACE2 mice, making this model incompatible with infections in the human lung. Hence, we developed lung-specific SARS-CoV-2 infection mouse models with surfactant protein B (SFTPB) and secretoglobin family 1a member 1 (Scgb1a1) promoters. After inoculation of 10(5) PFU of SARS-CoV-2 to the K18-hACE2, SFTPB-hACE2, and SCGB1A1-hACE2 models, the peak viral titer was detected at 2 days post-infection and then gradually decreased. In K18-hACE2 mice, the body temperature decreased by approximately 10°C, body weight decreased by over 20%, and the survival rate was reduced. However, SFTPB-hACE2 and SCGB1A1-hACE2 mice showed minimal clinical signs after infection. The virus targeted type I pneumocytes in K18-hACE2 mice; type II pneumocytes in SFTPB-hACE2 mice; and club, goblet, and ciliated cells in SCGB1A1-hACE2 mice. A time-dependent increase in severe lung lesions was detected in K18-hACE2 mice, whereas mild lesions developed in SFTPB-hACE2 and SCGB1A1-hACE2 mice. Spleen, small intestine, and brain lesions developed in K18-hACE2 mice but not in SFTPB-hACE2 and SCGB1A1-hACE2 mice. These newly developed SFTPB-hACE2 and SCGB1A1-hACE2 mice should prove useful to expand research on hACE2-mediated respiratory viruses.